GoBroad Medical Group

GoBroad Healthcare Group is a leading research-oriented hospital group in China, specializing in hematology, oncology, and cell therapy. Founded in 2017 and backed by major investors like Hillhouse Investment and Temasek, the group operates a network of specialized hospitals including Beijing GoBroad Boren Hospital and Shanghai GoBroad Hospital. The organization distinguishes itself by integrating high-end clinical treatment with a robust clinical research platform, making it a premier center for CAR-T cell therapy trials and hematopoietic stem cell transplantations. GoBroad provides comprehensive services ranging from advanced genomic diagnostics to complex immunotherapy, serving as a critical bridge between biopharmaceutical innovation and clinical application.